| Cell line name |
AP-1060 |
|---|
| Accession |
CVCL_1807 |
|---|
| Resource Identification Initiative |
To cite this cell line use: AP-1060 (RRID:CVCL_1807) |
|---|
| Comments |
Doubling time: ~48 hours (PubMed=15116119); ~80-100 hours (DSMZ=ACC-593).
Omics: Variations; Array-based CGH.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371. |
|---|
| Sequence variations |
- Gene deletion; HGNC; HGNC:12796; WT1; Zygosity=Homozygous (PubMed=29119387).
- Gene fusion; HGNC; HGNC:3495; ETV6 + HGNC; HGNC:8033; NTRK3; Name(s)=ETV6-NTRK3, TEL-TRKC (PubMed=29119387).
- Gene fusion; HGNC; HGNC:9113; PML + HGNC; HGNC:9864; RARA; Name(s)=PML-RARA (PubMed=15116119).
- Mutation; HGNC; HGNC:9864; RARA; Simple; p.Pro408Ser (c.1222C>T); Zygosity=Unspecified; Note=Equivalent to p.Pro900Ser in the PML-RARA fusion protein (PubMed=15116119).
|
|---|
| Disease |
Acute promyelocytic leukemia with PML-RARA (NCIt: C3182)
Acute promyelocytic leukemia (ORDO: Orphanet_520) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
45Y |
|---|
| Category |
Cancer cell line |
|---|
| STR profile |
Source(s): DSMZ=ACC-593
Markers:| Amelogenin | X,Y |
| CSF1PO | 12 |
| D2S1338 | 17,23 |
| D3S1358 | 14,16 |
| D5S818 | 12 |
| D7S820 | 10,11 |
| D8S1179 | 12 |
| D13S317 | 8,12 |
| D16S539 | 10,11 |
| D18S51 | 14,19 |
| D19S433 | 14 |
| D21S11 | 29,32.2 |
| FGA | 19,24 |
| Penta D | 9,13 |
| Penta E | 5,12 |
| TH01 | 9.3 |
| TPOX | 8,11 |
| vWA | 14,17 |
Run an STR similarity search on this cell line |
|---|
| Publications | PubMed=15116119; DOI=10.1038/sj.leu.2403372
Sun Y., Kim S.H., Zhou D.-C., Ding W., Paietta E.M., Guidez F., Zelent A., Ramesh K.H., Cannizzaro L.A., Warrell R.P. Jr., Gallagher R.E.
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
Leukemia 18:1258-1269(2004) PubMed=29119387; DOI=10.1007/s13402-017-0356-2
Chen S.-N., Nagel S., Schneider B., Dai H.-P., Geffers R., Kaufmann M., Meyer C., Pommerenke C., Thress K.S., Li J., Quentmeier H., Drexler H.G., MacLeod R.A.F.
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target -- a short report.
Cell. Oncol. (Dordr.) 41:93-101(2018) |
|---|
| Cross-references |
|---|
| Cell line collections (Providers) |
DSMZ; ACC-593
|
|---|
| Cell line databases/resources |
DSMZCellDive; ACC-593
|
|---|
| Biological sample resources |
BioSample; SAMN03473492
|
|---|
| Encyclopedic resources |
Wikidata; Q54750179
|
|---|
| Polymorphism and mutation databases |
Cosmic; 2750857
|
|---|
| Entry history |
|---|
| Entry creation | 04-Apr-2012 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 25 |
|---|
